Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03329196 |
Recruitment Status :
Completed
First Posted : November 1, 2017
Results First Posted : April 12, 2021
Last Update Posted : August 3, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
For Non-dialysis subjects with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.
For subjects not currently receiving ESAs, evaluate Hb correction and maintenance effect of MT-6548 and for subjects currently receiving ESAs, evaluate Hb conversion and maintenance effect of MT-6548
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Anemia; Non-dialysis Dependent Chronic Kidney Disease | Drug: MT-6548 Drug: Darbepoetin alfa | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 304 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase III, Open-label, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan |
Actual Study Start Date : | October 30, 2017 |
Actual Primary Completion Date : | January 8, 2019 |
Actual Study Completion Date : | August 9, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: MT-6548 |
Drug: MT-6548
Oral tablet
Other Names:
|
Active Comparator: Darbepoetin alfa |
Drug: Darbepoetin alfa
Subcutaneous |
- Mean Hb Level of Week 20 and Week 24 [ Time Frame: Up to Week 24 ]
- Mean Hb Level of Week 48 and Week 52 [ Time Frame: Up to Week 52 ]
- Hb Level at Each Assessment Time Point [ Time Frame: Up to Week 52 ]
- Percentage of Subjects With Hb Level at Each Assessment Time Point Within the Target Range During the Treatment Period [ Time Frame: Up to Week 52 ]
- Time to Reach the Target Hb Range in Correction Group Only [ Time Frame: Up to Week 52 ]
- Rate of Increase in Hb Level in Correction Group Only [ Time Frame: Up to Week 6 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of CKD
- eGFR < 60 mL/min/1.73m^2 during the screening period
- Not receiving dialysis for 8 weeks prior to the screening period, and not expected to start dialysis during the treatment period
- Correction group: Not being treated with ESAs for the recent 8 weeks prior to the screening period
- Conversion group: Being treated with ESAs for the recent 8 weeks prior to the screening period
- Mean of the two screening Hb levels closest in time to the baseline visit. Correction group: ≥8.0 g/dL and < 11.0 g/dL Conversion group: ≥9.0 g/dL and ≤12.5 g/dL
- Fluctuation between the two Hb levels closest in time to the baseline visit during the screening period less than 1.5 g/dL
- Serum ferritin ≥ 100 ng/mL, or TSAT ≥20% during the screening period
- Folate and vitamin B12 ≥ lower limit of normal during the screening period
Exclusion Criteria:
- Anemia due to a main cause other than CKD: sickle cell disease, myelodysplastic syndrome, bone marrow fibrosis, hematologic malignancy, hemolytic anemia, thalassemia, or pure red cell aplasia
- Active bleeding or recent blood loss within 8 weeks prior to the screening period
- RBC transfusion within 8 weeks prior to the screening period
- Received testosterone enanthate or mepitiostane within 8 weeks prior to the screening period
- AST, ALT, or total bilirubin >2.5 x upper limit of normal during the screening period
- Uncontrolled hypertension (diastolic blood pressure >110 mm Hg or systolic blood pressure >180 mm Hg) during the screening period and Day 1
-
Ophthalmic examinations during the screening period correspond to either of the following criteria;
- No available fundal findings
- Findings indicating the presence of active fundal disease
- Severe heart failure (New York Heart Association Class IV)
- Cerebrovascular disorder or acute coronary syndrome (hospitalization due to unstable angina or myocardial infarction), requiring hospitalization due to urgent percutaneous intervention for coronary or heart failure within 12 weeks prior to the screening period
- Current or history of malignancy. History of malignancy with no recurrence for the recent 5 years is not an exclusion criterion
- New onset or recurrent event of deep vein thrombosis or pulmonary embolism within 12 weeks prior to the screening period
- Current or history of hemosiderosis or hemochromatosis
- History of prior organ transplantation or scheduled organ transplant, or prior transplantation of hematopoietic stem cell or bone marrow
- Males and females of childbearing potential who are unwilling to use an acceptable method of contraception during the designated period (Males: during the study and 90 days after the last dose, females: during study and 30 days after the last dose)
- Females who are pregnant or breast feeding, or are predicted to be pregnant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03329196
Japan | |
Research site | |
Aichi, Japan | |
Research site | |
Chiba, Japan | |
Research site | |
Fukui, Japan | |
Research site | |
Fukuoka, Japan | |
Research site | |
Fukushima, Japan | |
Research site | |
Gunma, Japan | |
Research site | |
Hiroshima, Japan | |
Research site | |
Hokkaido, Japan | |
Research site | |
Hyogo, Japan | |
Research site | |
Ibaraki, Japan | |
Research site | |
Kagoshima, Japan | |
Research site | |
Kanagawa, Japan | |
Research site | |
Kochi, Japan | |
Research site | |
Kumamoto, Japan | |
Research site | |
Kyoto, Japan | |
Research site | |
Miyagi, Japan | |
Research site | |
Nagano, Japan | |
Research site | |
Nagasaki, Japan | |
Research site | |
Nara, Japan | |
Research site | |
Niigata, Japan | |
Research site | |
Oita, Japan | |
Research site | |
Okayama, Japan | |
Research site | |
Okinawa, Japan | |
Research site | |
Osaka, Japan | |
Research site | |
Saga, Japan | |
Research site | |
Saitama, Japan | |
Research site | |
Shiga, Japan | |
Research site | |
Shizuoka, Japan | |
Research site | |
Tokyo, Japan | |
Research site | |
Toyama, Japan | |
Research site | |
Yamanashi, Japan |
Study Director: | General Manager | Mitsubishi Tanabe Pharma Corporation |
Documents provided by Mitsubishi Tanabe Pharma Corporation:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Mitsubishi Tanabe Pharma Corporation |
ClinicalTrials.gov Identifier: | NCT03329196 |
Other Study ID Numbers: |
MT-6548-J01 |
First Posted: | November 1, 2017 Key Record Dates |
Results First Posted: | April 12, 2021 |
Last Update Posted: | August 3, 2021 |
Last Verified: | August 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Kidney Diseases Renal Insufficiency, Chronic Anemia Hematologic Diseases |
Urologic Diseases Renal Insufficiency Darbepoetin alfa Hematinics |